A new international study has brought encouraging news for people living with Type 2 diabetes.
Researchers have found that an experimental medicine called retatrutide may help lower blood sugar much more effectively than a placebo while also producing major weight loss.
The findings were published in The Lancet as part of the Phase 3 TRANSCEND-T2D-1 clinical trial.
Type 2 diabetes is one of the world’s fastest-growing health problems. It develops when the body cannot use insulin properly or cannot make enough insulin to keep blood sugar under control.
Over time, high blood sugar can damage the heart, kidneys, eyes, nerves and blood vessels.
Many people first try to manage the condition through healthy eating, exercise and weight loss, but these steps are not always enough. As the disease progresses, medicines are often needed to reduce blood sugar and lower the risk of serious complications.
Scientists have spent many years searching for medicines that can control blood sugar while also helping people lose excess weight. This is important because many people with Type 2 diabetes are also overweight or obese, and losing weight often improves blood sugar control and overall health.
Retatrutide belongs to a new generation of medicines known as triple hormone receptor agonists, sometimes called GLP-3 agonists. Unlike older medicines that mainly target one or two hormone pathways, retatrutide acts on three natural hormone receptors known as GLP-1, GIP and glucagon.
Together these hormones help control appetite, blood sugar, digestion and the amount of energy the body burns. By working on all three pathways at the same time, researchers believe the medicine may provide stronger benefits than existing treatments.
The Phase 3 study included adults with Type 2 diabetes whose blood sugar remained too high despite healthy eating and regular exercise. None of the participants were taking diabetes medicines when the trial began. Participants received either a weekly injection of retatrutide or a placebo for 40 weeks.
The results were impressive. People receiving retatrutide lowered their HbA1c, a measure of average blood sugar over the previous two to three months, by about 1.7% to 1.9%. Those receiving placebo experienced an average reduction of only 0.8%. Weight loss was also much greater. Participants taking retatrutide lost between 11.5% and 15.3% of their body weight on average, compared with only 2.6% in the placebo group.
Like many medicines that affect digestion, the most common side effects involved the stomach and intestines. Some participants experienced nausea or diarrhea, but these symptoms were usually mild to moderate and tended to improve as treatment continued.
Researchers believe this medicine could become an important option for people who need stronger treatment for Type 2 diabetes. However, they also emphasized that longer studies are still needed to confirm its long-term safety, effectiveness and possible rare side effects before it becomes widely available.
Overall, these findings are highly encouraging because they suggest that one medicine may improve blood sugar and produce meaningful weight loss at the same time. Nevertheless, this was only one Phase 3 trial.
Doctors should continue to balance the potential benefits with possible risks until longer-term evidence becomes available. Future studies will determine whether retatrutide can reduce diabetes complications and improve survival over many years.
If you care about diabetes, please read studies about Vitamin D and type 2 diabetes, and to people with diabetes, some fruits are better than others.
For more health information, please see recent studies that low calorie diets may help reverse diabetes, and 5 vitamins that may prevent complication in diabetes.
Source: University of North Carolina School of Medicine.
